JWCA
BCRX icon

J.W. Cole Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

J.W. Cole Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,600
Closed -$64K – 897
2024
Q1 		$64K Sell
12,600
-7,500
-37% -$42.2K ﹤0.01% 869
2023
Q4 		$120K Buy
20,100
+200
+1% +$1.16K 0.01% 788
2023
Q3 		$141K Sell
19,900
-2,300
-10% -$16.5K 0.01% 699
2023
Q2 		$156K Hold
22,200
– – 0.01% 717
2023
Q1 		$185K Hold
22,200
– – 0.01% 731
2022
Q4 		$255K Hold
22,200
– – 0.02% 620
2022
Q3 		$280K Sell
22,200
-100
-0.4% -$1.29K 0.02% 564
2022
Q2 		$236K Sell
22,300
-8,500
-28% -$87.7K 0.02% 619
2022
Q1 		$501K Sell
30,800
-6,000
-16% -$96.2K 0.03% 453
2021
Q4 		$510K Buy
36,800
+735
+2% +$9.73K 0.03% 455
2021
Q3 		$547K Buy
36,065
+15,665
+77% +$247K 0.04% 241
2021
Q2 		$323K Sell
20,400
-2,000
-9% -$27.2K 0.03% 561
2021
Q1 		$228K Hold
22,400
– – 0.02% 592
2020
Q4 		$167K Buy
+22,400
New +$115K 0.02% 604

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

J.W. Cole Advisors's BCRX Position: Q2 2024 in Review

J.W. Cole Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 12,600 shares — an estimated $64K sold.

J.W. Cole Advisors first reported a position in BCRX in Q4 2020 and held it in 14 quarters. The position peaked at $547K in Q3 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • J.W. Cole Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • J.W. Cole Advisors sold 12,600 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $64K.
  • J.W. Cole Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • J.W. Cole Advisors's BioCryst Pharmaceuticals position peaked at $547K in Q3 2021.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on J.W. Cole Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.